Real-world experience with teplizumab in stage 2 type 1 diabetes: a plain language summary

Summary What is this summary about? This is a plain language summary of a survey on experiences and views of (1) adults who were treated with teplizumab in early type 1 diabetes (T1D) and (2) caregivers of children who were treated with teplizumab in early T1D. Teplizumab is a treatment currently approved to delay the onset of stage 3 T1D in adults and children aged 8 years and older with stage 2 T1D. The survey collected information on: Characteristics and personal and family health history of the respondents. Experiences with finding out they or the child they care for had early T1D (screening and diagnosis). Thoughts and feelings before and after receiving treatment with teplizumab. Expectations for future health. This survey is the first to ask about the real-world experiences (outside of a clinical trial) of adults treated with teplizumab and caregivers of children treated with teplizumab. What were the results? Most people agreed with the statement that they were grateful for the chance to receive teplizumab (or for the child they care for to receive teplizumab). Most people also thought teplizumab would make their T1D easier to manage. Most people still worried about their condition getting worse and kept a close eye on their glucose levels after treatment with teplizumab. Even though they were concerned, they would recommend teplizumab to others and make the same decision for treatment if another family member had early T1D. What do the results of the survey mean? This survey captured the experiences and views of adults who received teplizumab or caregivers of children who received teplizumab. These findings are important for people who are considering screening for T1D or treatment with teplizumab, people who want to understand the possible consequences of having a screening test result showing early T1D, and clinicians who are considering teplizumab for their patients.